ALK and neoplasm: Thus, the combination of an ALK vaccine and ALK inhibitors, as expected, increased the anti-tumor efficacy [73] due to an increase of neoantigens and possible tumor microenvironment changes (e.g., more tumor-infiltrating lymphocytes).